Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Mechanisms of methotrexate resistance in osteosarcoma.

Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, Gorlick R.

Clin Cancer Res. 1999 Mar;5(3):621-7.

2.

mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.

Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, Gorlick R.

Mol Cancer Ther. 2003 Jun;2(6):535-41.

3.

Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.

Levy AS, Sather HN, Steinherz PG, Sowers R, La M, Moscow JA, Gaynon PS, Uckun FM, Bertino JR, Gorlick R; Children's Cancer Group Study.

J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95.

PMID:
12972803
4.

Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.

Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P.

Ann Oncol. 2004 Jan;15(1):151-60.

PMID:
14679136
5.

Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.

Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L.

J Pediatr. 2009 May;154(5):688-93. doi: 10.1016/j.jpeds.2008.11.030. Epub 2009 Jan 21.

PMID:
19159907
6.
7.

[Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].

Chen J, Gu LJ, Ying DM, Shen M, Wu HJ.

Ai Zheng. 2002 Dec;21(12):1335-40. Chinese.

PMID:
12520743
8.

Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.

Kaufman Y, Drori S, Cole PD, Kamen BA, Sirota J, Ifergan I, Arush MW, Elhasid R, Sahar D, Kaspers GJ, Jansen G, Matherly LH, Rechavi G, Toren A, Assaraf YG.

Cancer. 2004 Feb 15;100(4):773-82.

9.
10.

Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.

Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR.

Blood. 1997 Feb 1;89(3):1013-8.

11.

Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.

Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, Manara MC, Scotlandi K, Picci P, Serra M.

Eur J Cell Biol. 2003 Sep;82(9):483-93.

PMID:
14582536
12.

Impairments in antifolate transport are common in retinoblastoma tumor samples.

Gorlick RG, Abramson DH, Sowers R, Mazza BA, Dunkel IJ.

Pediatr Blood Cancer. 2008 Mar;50(3):573-6.

PMID:
17554792
13.

Molecular mechanisms of resistance to antifolates, a review.

Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E, Bertino JR.

Acta Biochim Pol. 1995;42(4):457-64. Review.

14.

Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines.

Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M.

Genes Chromosomes Cancer. 2009 Apr;48(4):289-309. doi: 10.1002/gcc.20640.

PMID:
19105235
15.

Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.

Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, Bernstein M, Beardsley GP, Krailo MD, Devidas M, Bertino JR, Meyers PA, Gorlick R.

Clin Cancer Res. 2003 Feb;9(2):837-44.

18.

Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.

Kobayashi H, Takemura Y, Ohnuma T.

Cancer Lett. 1998 Feb 27;124(2):135-42.

PMID:
9500202
19.

Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.

Göker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinherz P, Tan C, Berman E, et al.

Blood. 1995 Jul 15;86(2):677-84.

20.

Supplemental Content

Support Center